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Research Submission
Long-Term Safety Evaluation of  Ubrogepant for the Acute 
Treatment of  Migraine: Phase 3, Randomized, 52-Week 
Extension Trial
Jessica Ailani, MD; Richard B. Lipton, MD; Susan Hutchinson, MD; Kerry Knievel, DO; Kaifeng Lu, PhD;  
Matthew Butler, MD; Sung Yun Yu, BA; Michelle Finnegan, MPH; Lawrence Severt, MD; 
Joel M. Trugman, MD
Objective.—To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine.
Background.—Ubrogepant is an oral, calcitonin gene–related receptor antagonist in development for the acute treatment of 
migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in 
migraine headache pain, migraine-associated symptoms, and ability to function.
Methods.—This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or 
without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, 
ubrogepant 50  mg, or ubrogepant 100  mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care 
continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture back-
ground rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the 
primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received 
at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 
times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose.
Results.—The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 
100-mg group, and 417 in the usual care group). Participants were on average 42  years of age, 90% (1106/1230) female and 
85% (1043/1230) white, with an average BMI of 30  kg/m2. Throughout the trial, 21,454 migraine attacks were treated with 
31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66%) participants receiving 
ubrogepant 50  mg and 297/409 (73%) receiving ubrogepant 100  mg. The most commonly reported TEAE was upper respiratory 
tract infection (<12%); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10%) 
participants in the ubrogepant 50-mg group and 43/409 (11%) in the ubrogepant 100-mg group. Serious adverse events (SAEs) 
were reported by 9/404 (2%) participants in the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg 
group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent 
clinical adjudication committee of liver experts. There were no cases of Hy’s Law.
Conclusions.—Long-term intermittent use of ubrogepant 50 and 100  mg given as 1 or 2 doses per attack for the acute 
treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related  TEAEs and SAEs and 
discontinuations due to adverse events in this 1-year trial.
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INTRODUCTION
Migraine is a highly prevalent and burdensome 
chronic disease with attacks characterized by 1-sided 
pulsatile pain associated with sensitivity to light and 
sound, and nausea in various combinations.1 Based on 
the recent Global Burden of Disease study, migraine 
ranks second among the leading causes of years lived 
with disability,2,3 impacting not only a person’s daily 
living activities but having a negative effect on their 
families as well.4-9 Effective and safe treatment options 
are needed to help reduce the burden of migraine.
Several acute treatment options are currently 
available, including analgesics, nonsteroidal anti- 
inflammatory drugs (NSAIDs), ergot derivatives, and 
triptans.10-12 Even with the number of acute treat-
ments available, approximately 50% of those with mi-
graine are not satisfied with their acute treatment for 
migraine and most have significant unmet treatment 
needs.13 In the Migraine in America Symptoms and 
Treatment study,14 of the 15,133 adults with migraine, 
only 15% were using a triptan and 95.8% had at least 
1 unmet  treatment need.15 Among migraine-specific 
acute medications, ergot derivatives and triptans, 
though effective, are associated with safety and tol-
erability issues as well as contraindications.11,16 This 
supports the need for additional migraine-specific 
treatment options with desirable efficacy and safety 
profiles.
Calcitonin gene–related peptide (CGRP) plays an 
important role in migraine pathophysiology and as 
a result, small molecule CGRP receptor antagonists, 
known as gepants, are being studied for their efficacy in 
treating migraine.17,18 Ubrogepant is an oral gepant in 
development for the acute treatment of migraine. The 
efficacy and safety of ubrogepant have been shown 
in proof-of-concept and large, placebo-controlled tri-
als.19-21 The phase 3 ACHIEVE I and II single-attack 
trials met their co-primary endpoints for the 50- and 
100-mg doses, thereby establishing ubrogepant’s effi-
cacy. Rates of headache pain freedom 2 hours post-dose 
were significantly superior to placebo with ubrogepant 
25, 50, and 100 mg (P ≤ .01).20,21 In addition, the rates 
of absence of the most bothersome migraine-associ-
ated symptom (photophobia, phonophobia, or nausea) 
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at 2 hours were significantly greater with ubrogepant 
50 and 100  mg than placebo (P  ≤  .01), but not with 
ubrogepant 25 mg.
The primary objective of this phase 3, multicenter, 
randomized, 52-week extension trial was to evaluate 
the long-term safety and tolerability of inter mittent 
treatment with ubrogepant for the acute treatment 
of migraine over 1  year. Treatment groups included 
ubrogepant 50  mg, ubrogepant 100  mg, and a usual 
care arm. The usual care arm was included to contex-
tualize any hepatic safety findings over the course of 
this trial. Many treatments were included in the usual 
care arm, often treatments the patients were already 
using; therefore, non-laboratory adverse events (AEs) 
were not captured in relation to treatment in this arm.
METHODS
Trial Design.—This was a phase 3, multicenter, 
randomized, open-label, 52-week extension trial con-
ducted at 161 centers in the United States. The tri-
al protocol and all amendments were approved by 
properly constituted local and central institutional 
review boards. All participants provided written in-
formed consent before initiation of any trial-specific 
procedures. The trial was sponsored by Allergan plc, 
which included provision of trial treatment for those 
randomized to ubrogepant treatment arms. Changes 
to the original protocol are in Supplementary S1.
The first participant was enrolled September 
13, 2016 and the last participant completed August 
2, 2018. Participants were identified by the trial in-
vestigator and entered the trial after completing one 
of 2 randomized, double-blind, placebo-controlled, 
single-attack, phase 3 lead-in trials (ACHIEVE I, 
NCT02828020; ACHIEVE II, NCT02867709) and 
were re-randomized 1:1:1 to usual care, ubrogepant 
50 mg, or ubrogepant 100 mg.
Participants who were on a stable dose of  mi-
graine preventive medication were allowed to con-
tinue on their medication. Those with an alanine 
aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) level ≥1.5 times the upper limit of  nor-
mal (ULN) or bilirubin >1.5 mg/dL at screening were 
not included. Participants could not have any clin-
ically significant abnormalities in their electrocar-
diogram (ECG), physical examination, or laboratory 
test and could not have uncontrolled hypertension. 
Those with clinically significant cardiovascular or 
cerebrovascular disease or myocardial infarction, 
transient ischemic attack, or stroke within 6 months 
prior to Visit 1 were excluded from the trial. Use of 
moderate to strong CYP3A4 inhibitors and inducers 
was prohibited during the trial.
Although this was an open-label trial, randomiza-
tion to the ubrogepant dose was blinded. Participants 
randomized to ubrogepant took 2 tablets to treat each 
migraine attack. Participants in the ubrogepant 100-mg 
arm took two 50-mg ubrogepant tablets, whereas partici-
pants in the ubrogepant 50-mg arm took 1 ubrogepant 
50-mg tablet and 1 placebo tablet. Participants ran-
domized to ubrogepant could treat up to 8 migraine at-
tacks per 4-week interval during the 1-year trial period. 
If  participants returned to the site and received study 
medication prior to the end of a designated 4-week 
interval, they could treat more than 8 migraine attacks 
in a 4-week interval. Participants could treat headache 
pain of any severity (ie, mild, moderate, or severe). A 
qualifying migraine attack must have met all of the fol-
lowing conditions: at least 48 hours had passed since 
the last dose of ubrogepant, the participant had at least 
48 hours of pain freedom, less than 4 hours had passed 
since the headache started, the headache was not 
resolving on its own, and prohibited medications were 
not taken.
An optional second dose of ubrogepant or rescue 
medication, which could include analgesics (eg, acet-
aminophen, NSAIDs, opioids), anti-emetics, or trip-
tans, was allowed at least 2 hours after the initial dose 
if  the participant had a nonresponding migraine or 
migraine recurrence. The second dose of ubrogepant 
was the same as the first dose and could be taken 
2–48 hours after the initial ubrogepant dose. If  a sec-
ond dose was taken, the participant was not allowed to 
take rescue medication for at least 2 hours after the sec-
ond dose. If  the participant opted to take rescue medi-
cation instead, an optional second dose of ubrogepant 
was not allowed. Participants randomized to the usual 
care arm continued to treat their migraine attacks 
with medication that they had been taking historically. 
Their usual care medications were identified at Visit 1 
and any changes were recorded in the electronic case 
report form.
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After screening and randomization, visits occurred 
every 4 weeks for 1 year. The clinic visits for safety as-
sessments were at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 
48, and 52  weeks relative to the randomization visit. 
A safety follow-up visit occurred 4  weeks after the 
52-week visit or after early termination. Participants 
who did not treat a single migraine attack in the first 
6 months of the trial were discontinued.
An automated interactive Web response system 
(IWRS) was used to manage the randomization and 
treatment assignment. The sponsor’s biostatistician 
prepared the randomization codes. Investigational 
product was labeled with medication kit numbers. 
The IWRS provided the site with the specific medi-
cation kit number for each randomized participant 
in the ubrogepant arms at the time of randomization. 
Randomization was stratified by the participant’s 
historical triptan response and current preventive 
concomitant medication use, as determined in the lead- 
in trials. All participants, site personnel, and trial spon-
sor personnel were blinded to ubrogepant dose in this 
open-label trial.
An interim analysis was planned for when at least 
300 ubrogepant-treated participants who treated 
an average of  ≥2 migraine attacks per month were 
enrolled in the trial for 6  months and 200 ubrogep-
ant-treated participants who treated an average of  ≥2 
migraine attacks per month were enrolled for 1 year. 
At the time of  the interim database lock, the ubroge-
pant dosing assignments were unblinded to the spon-
sor; participants and investigators remained blinded. 
A full data analysis was conducted after trial com-
pletion and the data from the final 1-year trial are 
reported here.
Outcome Measures.—The primary outcomes 
were safety and tolerability, which included collec-
tion of AEs, clinical laboratory determinations, ECGs, 
vital sign measurements, physical examinations, and the 
Columbia-Suicide Severity Rating Scale at each clin-
ic visit. Investigators began each visit by querying for 
AEs by asking the participant a general, non-directed 
question such as “How have you been feeling since the 
last visit?” and then followed up with directed question-
ing, examination, and documentation, as appropriate. 
All AEs were coded using the Medical Dictionary for 
Regulatory Activities version 20.1 by the sponsor’s med-
ical coding group. The investigators were required to 
provide an assessment of the severity, the likelihood of 
a causal relationship to the study medication, and seri-
ousness of the event, document all actions taken with 
regard to the study medication, and detail any other 
treatment measures taken for the AE.
An independent clinical adjudication committee 
of liver experts was established for blinded adjudica-
tion of posttreatment elevations of ALT and/or AST 
≥3 times the ULN. Potential Hy’s Law cases were de-
fined as an elevation of ALT or AST value ≥3× the 
ULN and an elevated total bilirubin value ≥2× ULN, 
and, at the same time, an alkaline phosphatase value 
<2× ULN, all based on blood draws collected within 
a 24-hour period.22,23 A data safety monitoring board 
monitored unblinded safety data. Exploratory efficacy 
assessments of headache severity, migraine-associated 
symptoms (photophobia, phonophobia, nausea, and 
vomiting), use of rescue medications, use of optional 
second dose, and recurrence of headache pain were 
collected for ubrogepant treatment arms only. This 
manuscript’s focus is the safety outcomes; thus a com-
prehensive summary of efficacy findings will be re-
port ed separately.
Statistical Analysis.—The sample size was driven by 
regulatory safety requirements for duration of expo-
sure and number of participants rather than statistical 
considerations. The expected randomization was 1200 
participants with at least 70% completing 12 months of 
treatment and at least 50% expected to treat on average 
at least 2 migraine attacks per month.
The screened population included all screened 
participants who signed the informed consent. The 
intent-to-treat population included all randomized 
participants. The safety population included all ran-
domized participants who took at least 1 dose of 
ubrogepant treatment and all participants randomized 
to the usual care arm.
AE data were analyzed by calculating the fre-
quency and percentage of participants reporting the 
event in each treatment group. No formal statistical 
comparisons between treatment groups were planned 
or executed. The usual care population was included 
only to contextualize background rates of ALT/AST 
safety findings occurring in the ubrogepant-treated 
participants. Elevations of ALT/AST are often 
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asymptomatic; thus, the usual care arm provided within- 
study control of natural fluctuations in these evalu-
ations within a migraine population. The usual care 
population included participants who had been on and 
had tolerated their medication prior to enrollment. The 
participants in the usual care arm selected their usual 
acute treatment for migraine based on their prior treat-
ment experience; therefore, direct comparisons of AE 
rates between ubrogepant and the usual care arm can-
not be made given this self-selection. Many of the usual 
care arm participants had a history of tolerating their 
selected medication; therefore, AE rates in the usual 
care arm would not have reflected the introduction of 
a new treatment, as they did in the ubrogepant arms. 
Because previous experience with the usual care drug 
could have reduced the probability of experiencing 
/reporting safety or tolerability AEs, AEs reported in 
the usual care arm were not assessed for relatedness 
to the usual care medication. To directly evaluate the 
safety and tolerability profiles of acute treatments, 
enrolled participants should be naïve to each treatment 
before randomization, after which AE profiles can be 
compared.
AEs occurring after the screening visit were 
summarized for treatment-emergent adverse events 
(TEAEs), treatment-related TEAEs, serious adverse 
events (SAEs), and AEs leading to discontinuation. 
Treatment-related TEAEs were only determined for 
ubrogepant treatment arms.
Clinical laboratory assessments were summarized by 
treatment group. The adjudication committee findings 
were summarized by treatment group for participants 
with ALT or AST elevations ≥3 times the ULN.
Statistical analyses were conducted using SAS 
Version 9.4 or later (Cary, NC).
RESULTS
Participants and Extent of Exposure.—In this trial, 
1310 participants were screened, 1254 random-
ized, and 1230 included in the safety population 
(Fig. 1). Of the safety population, 665 participants were 
from the ACHIEVE I lead-in trial and 565 from the 
ACHIEVE II lead-in trial. In the ubrogepant 50-mg 
group, 404 participants treated 10,323 migraine at-
tacks with 1 or more doses of ubrogepant for a total of 
15,536 doses. In the ubrogepant 100-mg group, 409 
participants treated 11,131 migraine attacks with 1 or 
more doses of ubrogepant for a total of 16,432 doses. 
Over the course of the trial, an average of 13.2 and 14.8 
migraine attacks were treated with 1 dose of ubrogepant 
Fig. 1.—Participant disposition.
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50 and 100 mg, respectively, and an average of 12.3 and 
12.4 migraine attacks were treated with 2 or more 
doses of ubrogepant 50 and 100  mg, respectively. 
The average number of doses taken per participant 
over the 1-year trial period was 38.5 doses for ubrogepant 
50 mg and 40.2 doses for ubrogepant 100 mg.
Considering the maximum number of treated attacks 
in any given month, a total of  233 (29%) ubrogepant- 
treated participants treated 6 or more migraine attacks 
during at least 1 month in the trial (109 participants in 
the ubrogepant 50-mg group and 124 participants in 
the ubrogepant 100-mg group). Of these, a total of  72 
(9%) participants treated 8 or more migraine attacks 
in at least 1 month (30 participants in the ubrogep-
ant 50-mg group and 42 in the ubrogepant 100-mg 
group). Cumulatively, participants treated 6 or more 
migraines in a month in 740 months (334 months for 
those who took ubrogepant 50  mg and 406  months 
for those who took ubrogepant 100 mg). Participants 
treated 8 or more migraine attacks in a month for a 
total of  144 months (55 months for those who took 
ubrogepant 50 mg and 89 months for those who took 
100 mg).
Demographics and Clinical Characteristics.—In the 
safety population, participants were on average 
41.8 years of age (SD = 11.7), predominantly female 
(N = 1106/1230, 90%) and white (N = 1043/1230, 85%), 
with an average BMI of 29.9 kg/m2 (SD = 7.7). At the 
time of randomization, 306 (24.9%) participants in the 
safety population were on a preventive treatment for 
migraine (eg, topiramate, onabotulinumtoxinA, pro-
pranolol, amitriptyline), and use of preventive treat-
ment was evenly distributed across treatment groups 
(n = 102 [25%] in each group). In the safety popula-
tion, nearly all participants (99.5%) took at least 1 con-
comitant medication during the treatment period. The 
most common were ibuprofen (54.5%), combination 
aspirin-acetaminophen-caffeine (36.4%), sumatriptan 
(27.6%), and acetaminophen (25.6%). Overall, partic-
ipant demographics and clinical characteristics were 
similar in the ubrogepant and usual care arms.
Ubrogepant Adverse Events.—TEAEs occurred 
in 268 (66%) participants in the ubrogepant 50-mg 
group and in 297 (73%) participants in the ubrogepant 
100-mg group (Table 1). Most commonly reported 
TEAEs (≥2% of participants in any treatment group; 
Table 2) were upper respiratory tract infection, naso-
pharyngitis, sinusitis, urinary tract infection, influen-
za, and nausea. No increase in the incidence of TEAEs 
was noted with an increase in number of attacks treat-
ed per month (Supplementary S2). The incidence of 
TEAEs was similar across age (Supplementary S3), sex 
(Supplementary S4), and race subgroups (Supplemen-
tary S5).
Of the participants who had TEAEs, approxi-
mately 10% were considered related to ubrogepant 











TEAEs† 268 (66.3) 297 (72.6)
Treatment-related TEAEs† 42 (10.4) 43 (10.5)
On therapy SAE‡,§ 9 (2.2) 12 (2.9)
Deaths‡ 0 0
AEs leading to discontinuation¶ 9 (2.2) 11 (2.7)
†Treatment-emergent events were defined as those events that 
initially occurred or increased in intensity on or after the initial 
dose of treatment of the lead-in trial. An event that occurred 
after Visit 16 for participants with Visit 16 or more than 30 days 
after the last visit or last treatment, whichever was later, for 
participants without Visit 16 was not considered to be treatment 
emergent.
‡On-therapy events were defined as those events that occurred 
between the treatment start date of the lead-in trial and Visit 16, 
or within 30 days after the last visit or last treatment, whichever 
was later, for participants without Visit 16.
§All SAEs reported, by preferred term, ubrogepant 50 mg: 
cholecystitis acute, cholelithiasis, pneumonia, device allergy 
(allergic reaction due to Essure® implant), gait disturbance, 
hypertensive crisis, intestinal obstruction, pelvic inflammatory 
disease, postprocedural infection, sinus tachycardia, substance-
induced mood disorder; ubrogepant 100 mg: abortion, abortion 
spontaneous, acute respiratory failure, cholecystitis acute, 
cholelithiasis, colitis, diabetic ketoacidosis, ectopic pregnancy, 
gastroenteritis norovirus, hemiparesis, hiatus hernia, non-cardiac 
chest pain, pancreatitis acute, pneumonia, sepsis, subdural 
hematoma, suicidal ideation.
¶Includes events that occurred from screening to Visit 16, or 
within 30 days after the last visit or last treatment, whichever 
was later, for participants without Visit 16.
Only events that occurred on or after the randomization date are 
included except for AEs leading to discontinuation. Participants 
are counted only once within each category.
AE = adverse event; SAE = serious adverse event; TEAE = 
treatment-emergent adverse event.
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treatment by the investigator. The most commonly 
reported treatment-related TEAEs (≥1%) in any 
ubrogepant dose group were nausea (1.5 and 1.7% with 
ubrogepant 50 and 100  mg, respectively), dizziness 
(0.5 and 1.5%), and somnolence (1.5 and 1.2%). ALT 
increases (0.7 and 1.0%) and AST increases (0.5 and 
1.0%) also occurred with ubrogepant 50 and 100 mg.
Most TEAEs were mild or moderate in severity. 
Severe TEAEs were reported for 6.2 and 8.1% of par-
ticipants in ubrogepant 50-mg and ubrogepant 100-mg 
groups, respectively. Severe TEAEs that were reported 
for 3 or more participants in the ubrogepant groups 
were AST increase, cholelithiasis, nephrolithiasis, pneu-
monia, and sinusitis (each reported for 3 ubrogepant- 
treated participants); influenza, migraine, and nausea 
were each reported for 4 ubrogepant-treated 
participants.
SAEs were reported for 9/404 (2%) participants in 
the ubrogepant 50-mg group and 12/409 (3%) partici-
pants in the ubrogepant 100-mg group (Table 1). Only 
1 SAE was considered related to treatment by the in-
vestigator (sinus tachycardia), and this event occurred 
in a participant with a history of supraventricular 
tachycardia with ablation; the participant continued 
to take ubrogepant after this event without further 
complications. No deaths occurred during the trial. 
Discontinuations due to AEs were reported for 2–3% 
of the ubrogepant-treated participants. TEAEs leading 
to discontinuation assessed as related to treatment by 
the investigator were reported for 4 participants in 
the ubrogepant 50-mg group (nausea, thrombocytope-
nia, urticaria, and vomiting) and 4 in the ubrogepant 
100-mg group (abnormal ECG and extrasystolic beats; 
nausea and palpitations; pruritus; ALT and AST in-
crease). The event of thrombocytopenia was reported as 
unknown in terms of relatedness and imputed as related.
Cardiovascular Safety.—Frequency of  cardio-
vascular TEAEs in predefined categories of  cardiac 
arrhythmia, central nervous system (CNS)  vascular 
disorders, embolic and thrombotic events, hyper-
tension, and ischemic heart disease were general-
ly balanced between ubrogepant treatment groups 
(Table 3). No cardiovascular TEAEs occurred at a 
rate >2% in either ubrogepant treatment arm; few 
cardiovascular SAEs were reported. Two SAEs were 
reported in the category of  CNS vascular disorders, 
both considered not related to study medication. One 
event was an SAE of  hemiparesis; vascular etiology 
(ie, stroke) was ruled out and the investigator consid-
ered the event to be due to poorly controlled hypo-
thyroidism (Supplementary S6). The other SAE was 
a traumatic subdural hematoma due to a head injury. 
One cardiovascular SAE was considered related 
to treatment by the investigator (sinus tachycardia, 
details presented in Ubrogepant Adverse Events sec-
tion). No cardiovascular events related to myocardial in-
farction or stroke were reported in either ubrogepant 
treatment arm.
Table 2.—Common (≥2%)† Treatment-Emergent Adverse 










Nasopharyngitis 33 (8.2) 47 (11.5)
Upper respiratory tract infection 47 (11.6) 44 (10.8)
Sinusitis 28 (6.9) 26 (6.4)
Urinary tract infection 22 (5.4) 26 (6.4)
Influenza 17 (4.2) 25 (6.1)
Nausea 19 (4.7) 19 (4.6)
Bronchitis 13 (3.2) 18 (4.4)
Blood creatine phosphokinase 
increased
10 (2.5) 16 (3.9)
Alanine aminotransferase 
increased
9 (2.2) 15 (3.7)
Aspartate aminotransferase 
increased
7 (1.7) 14 (3.4)
Back pain 14 (3.5) 14 (3.4)
Nephrolithiasis 4 (1.0) 13 (3.2)
Dizziness 5 (1.2) 12 (2.9)
Anxiety 6 (1.5) 11 (2.7)
Cough 8 (2.0) 11 (2.7)
Diarrhea 10 (2.5) 11 (2.7)
Arthralgia 11 (2.7) 10 (2.4)
Gastroenteritis viral 7 (1.7) 10 (2.4)
Muscle strain 2 (0.5) 10 (2.4)
Depression 1 (3.2) 5 (1.2)
Migraine 6 (1.5) 4 (1.0)
Abdominal pain 4 (1.0) 2 (0.5)
Epididymitis§ 1 (3.2) 0 (0)
Testicular pain§ 1 (3.2) 0 (0)
†Only adverse events reported in ≥2% of participants (after 
rounding) in any treatment group are shown. Participants are 
counted only once within each preferred term.
‡Preferred terms were coded according to the Medical Dictionary 
of Regulatory Activity (MedDRA) Version 20.1.
§For sex-specific adverse events, percentages are relative to the 
number of participants of the appropriate sex.
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Hepatic Safety.—The mean changes in ALT and 
AST from baseline to postbaseline visits were similar 
across the ubrogepant treatment groups and the usu-
al care arm (Supplementary S7). Postbaseline hepatic 
laboratory values of  clinical interest are presented in 
Table 4. There were no cases of  confirmed Hy’s Law. 
One participant, while hospitalized with recurrent 
acute cholecystitis due to gallstones seen in the com-
mon bile duct, had rapid rises in ALT/AST and bili-
rubin levels. Following gallbladder removal, enzymes 
returned to normal (Supplementary S8). As there 
was an underlying cause for these ALT/AST and bil-
irubin elevations, this case did not meet criteria for 
Hy’s Law. Twenty cases of  ALT or AST elevations of 
≥3× ULN were reported, as follows: 4/398 (1.0%) 
in the  usual care  arm, 5/399 (1.3%) in the  ubrogepant 
50  mg  arm, and 11/406 (2.7%) in the  ubrogepant 
100 mg arm. All ≥3× ULN ALT or AST cases were 
adjudicated by an  independent panel of  liver ex-
perts blinded to ubrogepant dose (Supplementary 
S8). Out of  the 20 cases, 17 (4 usual care, 3 ubrogep-
ant 50 mg, and 10 ubrogepant 100 mg) were judged 
Unlikely Related to study medication. Two cases (both 
ubrogepant 50  mg) were judged Possibly Related  
with confounding factors reported (increased alco-
hol and acetaminophen use; dilated bile duct). Only 1 
case of  ALT or AST elevations of  ≥3× ULN (ubroge-
pant 100  mg) was judged Probably Related; howev-
er, confounding factors were noted (prednisone use 
for exacerbation of  psoriasis prior to rise in ALT/
AST). All cases of  ALT or AST elevation ≥3× ULN 
resolved in those who continued ubrogepant dosing.
Usual Care Adverse Events.—As noted, the usual 
care population was included to examine variability 
in hepatic laboratory parameters to help contextual-
ize the hepatic safety data. The trial was not designed 
to specifically compare AEs between these groups due 
to the differences in the usual care and ubrogepant- 
treated populations, as outlined above. A total 
of  271/417 participants (65.0%) reported a TEAE; 
relatedness was not assessed for the usual care arm. 
The most common (≥2% participants in any group; 
Supplementary S9) were upper respiratory tract in-
fection (n = 48/417, 11.5%), nasopharyngitis (n = 33, 
7.9%), sinusitis (n  =  25, 6.0%), urinary tract infec-
tion (n  =  23, 5.5%), and influenza (n  =  21, 5.0%). 
Severe TEAEs were reported for 6.2% of participants. 
Serious AEs were reported by 17 participants (4.1%) 
(Supplementary S10). No deaths were reported and 4 
participants (1.0%) reported TEAEs that led to dis-
continuation.
DISCUSSION
This phase 3, long-term safety evaluation fol-
lowed 813 participants treated intermittently with 
ubrogepant 50 or 100 mg over the course of  1 year. 
A total of  21,454 migraine attacks were treated with 
31,968 doses of  ubrogepant. Participants treated 
≥8 migraine attacks with ubrogepant 50 or 100  mg 
in a total of  144  months. Overall, there was a low 
Table 3.—Treatment-Emergent Cardiovascular Adverse 











Cardiac arrhythmias 4 (1.0) 5 (1.2)
Arrhythmia 0 1 (0.2)
ECG QRS complex prolonged 0 1 (0.2)
Extrasystoles 0 1 (0.2)
Sinus tachycardia‡ 1 (0.2) 1 (0.2)
Ventricular extrasystoles 0 1 (0.5)
Atrioventricular block first degree 1 (0.2) 0
Cardiac flutter 1 (0.2) 0
Sinus bradycardia 1 (0.2) 0
CNS vascular disorder/embolic and 
thrombotic events
0 2 (0.5)
Hemiparesis†,‡,§ 0 1 (0.2)
Traumatic subdural hematoma‡ 0 1 (0.2)
Hypertension 13 (3.2) 11 (2.7)
Hypertension 8 (2.0) 7 (1.7)
Blood pressure diastolic increased 1 (0.2) 2 (0.5)
Blood pressure increased 3 (0.7) 2 (0.5)
Hypertensive crisis‡ 1 (0.2) 0
Prehypertension 1 (0.2) 0
Ischemic heart disease 2 (0.5) 2 (0.5)
Angina pectoris 2 (0.5) 2 (0.5)
†Each category is based on predefined standard groups of 
Preferred Terms (narrow Standard MedDRA Queries).
‡Reported as a serious adverse event.
§The participant with hemiparesis had negative imaging for any 
vascular events and stroke was ruled out as a possible cause. 
The investigator attributed the event to severe uncontrolled 
hypothyroidism.
CNS = central nervous system; TEAE = treatment-emergent 
adverse event.
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ALT (U/L)      
≥1 × ULN 114/397 (28.7) 117/399 (29.3) 122/406 (30.0)
≥1.5 × ULN 38/397 (9.6) 38/399 (9.5) 55/406 (13.5)
≥2 × ULN 16/397 (4.0) 14/399 (3.5) 33/406 (8.1)
≥3 × ULN 4/397 (1.0) 4/399 (1.0) 8/406 (2.0)
≥5 × ULN 1/397 (0.3) 2/399 (0.5) 4/406 (1.0)
≥10 × ULN 0/397 0/399 1/406 (0.2)
≥20 × ULN 0/397 0/399 0/406
AST (U/L)      
≥1 × ULN 60/397 (15.1) 55/399 (13.8) 70/406 (17.2)
≥1.5 × ULN 13/397 (3.3) 16/399 (4.0) 28/406 (6.9)
≥2 × ULN 5/397 (1.3) 9/399 (2.3) 10/406 (2.5)
≥3 × ULN 2/397 (0.5) 2/399 (0.5) 9/406 (2.2)
≥5 × ULN 1/397 (0.3) 1/399 (0.3) 4/406 (1.0)
≥10 × ULN 0/397 0/399 2/406 (0.5)
≥20 × ULN 0/397 0/399 1/406 (0.2)
ALT or AST (U/L)      
≥1 × ULN 123/397 (31.0) 124/399 (31.1) 134/406 (33.0)
≥1.5 × ULN 42/397 (10.6) 41/399 (10.3) 59/406 (14.5)
≥2 × ULN 19/397 (4.8) 20/399 (5.0) 35/406 (8.6)
≥3 × ULN 4/397 (1.0) 5/399 (1.3) 11/406 (2.7)
≥5 × ULN 1/397 (0.3) 2/399 (0.5) 6/406 (1.5)
≥10 × ULN 0/397 0/399 2/406 (0.5)
≥20 × ULN 0/397 0/399 1/406 (0.2)
Bilirubin total (μmol/L)      
≥1 × ULN 14/397 (3.5) 16/399 (4.0) 18/406 (4.4)
≥1.5 × ULN 3/397 (0.8) 5/399 (1.3) 2/406 (0.5)
≥2 × ULN 1/397 (0.3) 3/399 (0.8) 2/406 (0.5)
≥3 × ULN 0/397 1/399 (0.3) 1/406 (0.2)
≥5 × ULN 0/397 0/399 0/406
≥10 × ULN 0/397 0/399 0/406
≥20 × ULN 0/397 0/399 0/406
Alkaline phosphatase (U/L)      
≥1 × ULN 35/397 (8.8) 48/399 (12.0) 36/406 (8.9)
≥1.5 × ULN 3/397 (0.8) 1/399 (0.3) 1/406 (0.2)
≥2 × ULN 1/397 (0.3) 1/399 (0.3) 0/406
≥3 × ULN 0/397 0/399 0/406
≥5 × ULN 0/397 0/399 0/406
≥10 × ULN 0/397 0/399 0/406
≥20 × ULN 0/397 0/399 0/406
Concurrent elevations†      
ALT or AST ≥3× ULN and bilirubin 0/397 0/399 1/406 (0.2)
total ≥1.5× ULN      
ALT or AST ≥3× ULN and bilirubin 0/397 0/399 1/406 (0.2)
total ≥2× ULN      
Potential Hy's law‡      
ALT or AST ≥3× ULN and bilirubin 0/397 0/399 1/406 (0.2)
total ≥2× ULN and ALP <2× ULN      
†Concurrent elevations are from the same day.
‡One participant met biochemical Hy’s Law criteria due to an episode of acute cholecystitis; however, there were no confirmed Hy’s 
Law cases.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal value.
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incidence of  TEAEs, which were mostly mild to mod-
erate in severity with the majority considered unre-
lated to treatment by the investigator. There was no 
apparent relationship between TEAE incidence and 
the number of  attacks treated per month. In addi-
tion, no hepatic or cardiovascular safety issues were 
noted. Additionally the rates of  SAEs and discon-
tinuations due to AEs were low, with less than 3% 
of  participants treated with ubrogepant experienc-
ing either. Based on these results, long-term, inter-
mittent use of  ubrogepant for the acute treatment of 
migraine appears to be safe and well tolerated.
Previously, the gepant class had been evaluated 
for their efficacy and safety in the acute treatment of 
migraine and showed promising efficacy, but safety 
concerns halted their development.24-27 The results of 
1 phase 2B19 and 2 phase 320,21 clinical trials demon-
strated that ubrogepant is well tolerated and effec-
tive for the acute treatment of migraine attacks. The 
most common (≥2% of participants in any treatment 
group) TEAEs in the ACHIEVE I phase 3 trial were 
nausea, somnolence, and dry mouth and in the phase 
3 ACHIEVE II trial were nausea and dizziness.20,21 No 
serious AEs were reported within 48 hours postdose 
in either trial. No participants discontinued because 
of AEs and no hepatic safety signals were identified in 
either trial.
Overall, data from this trial further support the 
safety profile of ubrogepant. With regard to hepatic 
safety, 2% (16/805) of participants randomized to 
ubrogepant had increases in their ALT/AST ≥3× the 
ULN versus 1% (4/397) of participants in the usual 
care arm. There were no concerning hepatic safety find-
ings and 13 of the 16 cases in the ubrogepant groups 
were adjudicated as Unlikely Related to trial treatment. 
Two cases were judged Possibly Related and 1 case was 
judged Probably Related; however, confounding fac-
tors were noted in each case (increased alcohol and 
acetaminophen use; dilated bile duct; and prednisone 
use). These findings, along with the observation that all 
aminotransferase elevations ≥3× ULN resolved in par-
ticipants who continued ubrogepant dosing, indicate 
that there were no clinically meaningful hepatic safety 
signals for ubrogepant in this trial. These data also help 
to confirm findings from the dedicated hepatic safety 
trial in healthy volunteers, where ubrogepant was 
found to be safe and well tolerated, with no hepatic 
safety signals noted following high-frequency dosing 
for 12 weeks.28
The efficacy of ubrogepant has been demonstrated 
in 2 phase 3, multicenter, randomized, double-blind, 
placebo-controlled single-attack trials (ACHIEVE I 
and II).20,21 The percentage of participants reporting 
pain freedom 2 hours post-initial dose was significantly 
greater in the ubrogepant arms than the placebo arms of 
both trials. In addition, the proportion of participants 
reporting absence of the most bothersome migraine- 
associated symptom (photophobia, phonophobia, or 
nausea) at 2 hours was greater in the ubrogepant arms 
than the placebo arms of both trials. While the present 
trial was designed as a long-term safety trial, efficacy 
measures were collected for the ubrogepant treatment 
arms.29 Participants reported pain freedom at 2 hours 
for an average of 23% of attacks treated with ubrogepant 
50  mg and 25% of attacks treated with ubrogepant 
100 mg. Pain relief  at 2 hours was achieved for 65% of 
attacks treated with ubrogepant 50 mg and 68% treated 
with ubrogepant 100 mg. Efficacy was maintained over 
the 1-year trial period.
As with most trials, this trial does have some lim-
itations that may impact the interpretation and gener-
alizability of the data. First, exclusion of those with 
certain diseases, disease states, and clinically significant 
conditions as outlined in the methods section may limit 
these data from being reflective of real-world experi-
ence. However, inclusion of participants with ALT/AST 
elevations ≤1.5× the ULN and bilirubin <1.5  mg/dL 
increases the generalizability of the data. Second, dif-
ferences in participant populations and trial designs 
limit the ability to compare safety profiles of differ-
ent acute treatment options for migraine. In particu-
lar, headache pain of any severity was allowed to be 
treated in this trial, which may not be consistent with 
other reported trials. Third, commonly reported AEs 
of nausea and dizziness can be symptoms associated 
with a migraine attack, making it is difficult to dis-
cern the causality of these AEs. Finally, the usual care 
arm was included to identify possible fluctuations in 
hepatic laboratory parameters to help contextualize the 
hepatic safety data. Interpretation of the AE data in 
the usual care arm, and comparison to the ubrogepant 
arms, is limited as the usual care arm consisted of 
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participants who had been on and had tolerated their 
medication; therefore, AE rates do not reflect the intro-
duction of a new treatment. The usual care arm of the 
present study does, however, reflect similar AE rates 
observed in other long-term safety studies conducted 
on alternative acute treatments for migraines, in which 
overall AE rates ranged from 45 to 68% of patients for 
up to an 18-month period.30-32
CONCLUSIONS
Long-term intermittent use of ubrogepant 50 and 
100 mg given as 1 or 2 doses per attack for the acute 
treatment of migraine was safe and well tolerated, as 
indicated by a low incidence of TEAEs and low rate of 
SAEs and discontinuations due to AEs, in this 1-year 
trial.
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